{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T10:33:32Z","timestamp":1777286012271,"version":"3.51.4"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T00:00:00Z","timestamp":1564099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["091182"],"award-info":[{"award-number":["091182"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["102731"],"award-info":[{"award-number":["102731"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["090532"],"award-info":[{"award-number":["090532"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Oxford Medical Sciences Division Internal","award":["0005128"],"award-info":[{"award-number":["0005128"]}]},{"DOI":"10.13039\/100006662","name":"National Institute on Handicapped Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["G0902418"],"award-info":[{"award-number":["G0902418"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_12025"],"award-info":[{"award-number":["MC_UU_12025"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"Abstract<\/jats:title>\n \n STUDY QUESTION<\/jats:title>\n What effect does cancer treatment have on levels of spontaneous selfish fibroblast growth factor receptor 2 (FGFR2) point mutations in human sperm?<\/jats:p>\n <\/jats:sec>\n \n SUMMARY ANSWER<\/jats:title>\n Chemotherapy and radiotherapy do not increase levels of spontaneous FGFR2 mutations in sperm but, unexpectedly, highly-sterilizing treatments dramatically reduce the levels of the disease-associated c.755C\u2009>\u2009G (Apert syndrome) mutation in sperm.<\/jats:p>\n <\/jats:sec>\n \n WHAT IS KNOWN ALREADY<\/jats:title>\n Cancer treatments lead to short-term increases in gross DNA damage (chromosomal abnormalities and DNA fragmentation) but the long-term effects, particularly at the single nucleotide resolution level, are poorly understood. We have exploited an ultra-sensitive assay to directly quantify point mutation levels at the FGFR2 locus.<\/jats:p>\n <\/jats:sec>\n \n STUDY DESIGN, SIZE, DURATION<\/jats:title>\n \u2018Selfish\u2019 mutations are disease-associated mutations that occur spontaneously in the sperm of most men and their levels typically increase with age. Levels of mutations at c.752\u2013755 of FGFR2 (including c.755C\u2009>\u2009G and c.755C\u2009>\u2009T associated with Apert and Crouzon syndromes, respectively) in semen post-cancer treatment from 18 men were compared to levels in pre-treatment samples from the same individuals (n\u2009=\u20094) or levels in previously screened population controls (n\u2009=\u200999).<\/jats:p>\n <\/jats:sec>\n \n PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n Cancer patients were stratified into four different groups based on the treatments they received and the length of time for spermatogenesis recovery. DNA extracted from semen samples was analysed using a previously established highly sensitive assay to identify mutations at positions c.752\u2013755 of FGFR2. Five to ten micrograms of semen genomic DNA was spiked with internal controls for quantification purposes, digested with MboI restriction enzyme and gel extracted. Following PCR amplification, further MboI digestion and a nested PCR with barcoding primers, samples were sequenced on Illumina MiSeq. Mutation levels were determined relative to the spiked internal control; in individuals heterozygous for a nearby common single nucleotide polymorphism (SNP), mutations were phased to their respective alleles.<\/jats:p>\n <\/jats:sec>\n \n MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n Patients treated with moderately-sterilizing alkylating regimens and who recovered spermatogenesis within <3\u00a0years after therapy (Group 3, n\u2009=\u20094) or non\u2009\u2212\u2009alkylating chemotherapy and\/or low gonadal radiation doses (Group 1, n\u2009=\u20094) had mutation levels similar to untreated controls. However, patients who had highly-sterilizing alkylating treatments (i.e. >5\u00a0years to spermatogenesis recovery) (Group 2, n\u2009=\u20097) or pelvic radiotherapy (Group 4, n\u2009=\u20093) exhibited c.755C\u2009>\u2009G mutation levels at or below background. Two patients (A and B) treated with highly-sterilizing alkylating agents demonstrated a clear reduction from pre-treatment levels; however pre-treatment samples were not available for the other patients with low mutation levels. Therefore, although based on their age we would expect detectable levels of mutations, we cannot exclude the possibility that these patients also had low mutation levels pre-treatment. In three patients with low c.755C\u2009>\u2009G levels at the first timepoint post-treatment, we observed increasing mutation levels over time. For two such patients we could phase the mutation to a nearby polymorphism (SNP) and determine that the mutation counts likely originated from a single or a small number of mutational events.<\/jats:p>\n <\/jats:sec>\n \n LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n This study was limited to 18 patients with different treatment regimens; for nine of the 18 patients, samples from only one timepoint were available. Only 12 different de novo substitutions at the FGFR2 c.752\u2013755 locus were assessed, two of which are known to be disease associated.<\/jats:p>\n <\/jats:sec>\n \n WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n Our data add to the body of evidence from epidemiological studies and experimental data in humans suggesting that male germline stem cells are resilient to the accumulation of spontaneous mutations. Collectively, these data should provide physicians and health-care professionals with reassuring experimental-based evidence for counselling of male cancer patients contemplating their reproductive options several years after treatment.<\/jats:p>\n <\/jats:sec>\n \n STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n This work was primarily supported by grants from the Wellcome (grant 091182 to AG and AOMW; grant 102\u2009731 to AOMW), the University of Oxford Medical Sciences Division Internal Fund (grant 0005128 to GJM and AG), the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre Programme (to AG) and the US National Institutes of Health (to MLM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. None of the authors has any conflicts of interest to declare.<\/jats:p>\n <\/jats:sec>\n \n TRIAL REGISTRATION NUMBER<\/jats:title>\n NA<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/humrep\/dez090","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T15:20:29Z","timestamp":1557415229000},"page":"1404-1415","source":"Crossref","is-referenced-by-count":11,"title":["The impact of chemo- and radiotherapy treatments on selfish de novo FGFR2 mutations in sperm of cancer survivors"],"prefix":"10.1093","volume":"34","author":[{"given":"Geoffrey J","family":"Maher","sequence":"first","affiliation":[{"name":"Clinical Genetics Group, MRC-Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK"},{"name":"Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Bernkopf","sequence":"additional","affiliation":[{"name":"Clinical Genetics Group, MRC-Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK"},{"name":"Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Koelling","sequence":"additional","affiliation":[{"name":"Clinical Genetics Group, MRC-Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK"},{"name":"Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew O M","family":"Wilkie","sequence":"additional","affiliation":[{"name":"Clinical Genetics Group, MRC-Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK"},{"name":"Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin L","family":"Meistrich","sequence":"additional","affiliation":[{"name":"Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Goriely","sequence":"additional","affiliation":[{"name":"Clinical Genetics Group, MRC-Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK"},{"name":"Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,7,26]]},"reference":[{"key":"2019080918245909100_ref1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/ncomms7684","article-title":"The genome-wide effects of ionizing radiation on mutation induction in the mammalian germline","volume":"6","author":"Adewoye","year":"2015","journal-title":"Nat Commun"},{"key":"2019080918245909100_ref2","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.fertnstert.2013.07.1974","article-title":"The determination of reproductive safety in men during and after cancer treatment","volume":"100","author":"Choy","year":"2013","journal-title":"Fertil Steril"},{"key":"2019080918245909100_ref3","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.1984.2.6.571","article-title":"Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy","volume":"2","author":"Cunha","year":"1984","journal-title":"J Clin Oncol"},{"key":"2019080918245909100_ref4","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0360-3016(99)00338-7","article-title":"Recovery of sperm production following radiation therapy for Hodgkin's disease after induction chemotherapy with mitoxantrone, vincristine, vinblastine, and prednisone (NOVP)","volume":"46","author":"Dubey","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2019080918245909100_ref5","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.1073\/pnas.0803379105","article-title":"Drug-sensitive FGFR2 mutations in endometrial carcinoma","volume":"105","author":"Dutt","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019080918245909100_ref6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/bdrc.20141","article-title":"Spermatogonial stem cells: mouse and human comparisons","volume":"87","author":"Dym","year":"2009","journal-title":"Birth Defects Res C Embryo Today"},{"key":"2019080918245909100_ref7","first-page":"44","article-title":"NOVP chemotherapy for Hodgkin's disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18, and 21","volume":"63","author":"Frias","year":"2003","journal-title":"Cancer Res"},{"key":"2019080918245909100_ref8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0027-5107(84)90060-5","article-title":"Response of mouse spermatogonial stem cells to X-ray induction of heritable reciprocal translocations","volume":"126","author":"Generoso","year":"1984","journal-title":"Mutat Res"},{"key":"2019080918245909100_ref9","doi-asserted-by":"crossref","first-page":"20152","DOI":"10.1073\/pnas.1311381110","article-title":"Contributions of intrinsic mutation rate and selfish selection to levels of de novo HRAS mutations in the paternal germline","volume":"110","author":"Giannoulatou","year":"2013","journal-title":"Proc Nat Acad Sc USA"},{"key":"2019080918245909100_ref10","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1085710","article-title":"Evidence for selective advantage of pathogenic FGFR2 mutations in the male germ line","volume":"301","author":"Goriely","year":"2003","journal-title":"Science"},{"key":"2019080918245909100_ref11","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1073\/pnas.0500267102","article-title":"Gain-of-function amino acid substitutions drive positive selection of FGFR2 mutations in human spermatogonia","volume":"102","author":"Goriely","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019080918245909100_ref12","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/ng.470","article-title":"Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors","volume":"41","author":"Goriely","year":"2009","journal-title":"Nat Genet"},{"key":"2019080918245909100_ref13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ajhg.2011.12.017","article-title":"Paternal age effect mutations and selfish spermatogonial selection: causes and consequences for human disease","volume":"90","author":"Goriely","year":"2012","journal-title":"Am J Hum Genet"},{"key":"2019080918245909100_ref14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/pbc.24679","article-title":"The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the childhood Cancer survivor study","volume":"61","author":"Green","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"2019080918245909100_ref15","doi-asserted-by":"crossref","first-page":"14611","DOI":"10.1038\/s41598-018-33066-x","article-title":"Multisite de novo mutations in human offspring after paternal exposure to ionizing radiation","volume":"8","author":"Holtgrewe","year":"2018","journal-title":"Sci Rep"},{"key":"2019080918245909100_ref16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jncimonographs\/lgi003","article-title":"Spermatogenesis after cancer treatment: damage and recovery","volume":"34","author":"Howell","year":"2005","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2019080918245909100_ref17","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1095\/biolreprod.102.012575","article-title":"Functional assessment of self-renewal activity of male Germline stem cells following cytotoxic damage and serial transplantation","volume":"68","author":"Kanatsu-Shinohara","year":"2003","journal-title":"Biol Reprod"},{"key":"2019080918245909100_ref18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0027-5107(84)90034-4","article-title":"Induction of congenital malformations in the offspring of male mice treated with X-rays at pre-meiotic and post-meiotic stages","volume":"125","author":"Kirk","year":"1984","journal-title":"Mutat Res"},{"key":"2019080918245909100_ref19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature11396","article-title":"Rate of de novo mutations and the importance of father's age to disease risk","volume":"488","author":"Kong","year":"2012","journal-title":"Nature"},{"key":"2019080918245909100_ref20","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1158\/1078-0432.CCR-15-2317","article-title":"Genetic effect of chemotherapy exposure in children of testicular Cancer survivors","volume":"22","author":"Kryukov","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2019080918245909100_ref21","author":"Li","year":"2013"},{"key":"2019080918245909100_ref22","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1073\/pnas.1521325113","article-title":"Visualizing the origins of selfish de novo mutations in individual seminiferous tubules of human testes","volume":"113","author":"Maher","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019080918245909100_ref23","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1101\/gr.239186.118","article-title":"Selfish mutations dysregulating RAS-MAPK signaling are pervasive in aged human testes","volume":"28","author":"Maher","year":"2018","journal-title":"Genome Res"},{"key":"2019080918245909100_ref24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.stemcr.2014.06.007","article-title":"Enhanced fitness of adult spermatogonial stem cells bearing a paternal age-associated FGFR2 mutation","volume":"3","author":"Martin","year":"2014","journal-title":"Stem Cell Reports"},{"key":"2019080918245909100_ref25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.fertnstert.2016.10.001","article-title":"Impact of Hodgkin or non-Hodgkin lymphoma and their treatments on sperm aneuploidy: a prospective study by the French CECOS network","volume":"107","author":"Martinez","year":"2017","journal-title":"Fertil Steril"},{"key":"2019080918245909100_ref26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0027-5107(00)00085-3","article-title":"Minisatellite mutation frequency in human sperm following radiotherapy","volume":"453","author":"May","year":"2000","journal-title":"Mutat Res"},{"key":"2019080918245909100_ref27","first-page":"370","article-title":"Low levels of chromosomal mutations in germ cells derived from doxorubicin-treated stem spermatogonia in the mouse","volume":"50","author":"Meistrich","year":"1990","journal-title":"Cancer Res"},{"key":"2019080918245909100_ref28","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1002\/1097-0142(19921201)70:11<2703::AID-CNCR2820701123>3.0.CO;2-X","article-title":"Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas","volume":"70","author":"Meistrich","year":"1992","journal-title":"Cancer"},{"key":"2019080918245909100_ref29","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1200\/JCO.1997.15.12.3488","article-title":"Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease","volume":"15","author":"Meistrich","year":"1997","journal-title":"J Clin Oncol"},{"key":"2019080918245909100_ref30","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/339466","article-title":"Genetic disease in offspring of long-term survivors of childhood and adolescent cancer treated with potentially mutagenic therapies","volume":"70","author":"Meistrich","year":"2002","journal-title":"Am J Hum Genet"},{"key":"2019080918245909100_ref31","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.fertnstert.2013.08.010","article-title":"Effects of chemotherapy and radiotherapy on spermatogenesis in humans","volume":"100","author":"Meistrich","year":"2013","journal-title":"Fertil Steril"},{"key":"2019080918245909100_ref32","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/14647273.2011.634480","article-title":"Banking sperm is only the first of many decisions for men: what healthcare professionals and men need to know","volume":"14","author":"Pacey","year":"2011","journal-title":"Hum Fertil"},{"issue":"Suppl 2","key":"2019080918245909100_ref33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/annonc\/5.suppl_2.S97","article-title":"Hodgkin's disease with a mediastinal mass greater than 10 cm: results of four different treatment approaches","volume":"5","author":"Preti","year":"1994","journal-title":"Ann Oncol"},{"key":"2019080918245909100_ref34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1200\/JCO.1993.11.2.239","article-title":"Long-term reduction in sperm count after chemotherapy with and without radiation therapy for non-Hodgkin's lymphomas","volume":"11","author":"Pryzant","year":"1993","journal-title":"J Clin Oncol"},{"key":"2019080918245909100_ref35","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1371\/journal.pbio.0050224","article-title":"The molecular anatomy of spontaneous germline mutations in human testes","volume":"5","author":"Qin","year":"2007","journal-title":"PLoS Biol"},{"key":"2019080918245909100_ref36","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cncr.21185","article-title":"Sperm cryopreservation before cancer chemotherapy helps in the emotional battle against cancer","volume":"104","author":"Saito","year":"2005","journal-title":"Cancer"},{"key":"2019080918245909100_ref37","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12885-016-2236-y","article-title":"Birth rates among male cancer survivors and mortality rates among their offspring: a population-based study from Sweden","volume":"16","author":"Tang","year":"2016","journal-title":"BMC Cancer"},{"key":"2019080918245909100_ref38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0027-5107(96)00029-2","article-title":"Mutagenicity of anticancer drugs in mammalian germ cells","volume":"355","author":"Witt","year":"1996","journal-title":"Mutat Res"},{"key":"2019080918245909100_ref39","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/1098-2280(2000)36:2<134::AID-EM8>3.0.CO;2-D","article-title":"Frequency of minisatellite repeat number changes at the MS205 locus in human sperm before and after cancer chemotherapy","volume":"36","author":"Zheng","year":"2000","journal-title":"Environ Mol Mutagen"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humrep\/advance-article-pdf\/doi\/10.1093\/humrep\/dez090\/29007403\/dez090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/34\/8\/1404\/29115099\/dez090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T07:42:13Z","timestamp":1568965333000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/34\/8\/1404\/5539576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,26]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,7,26]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/dez090","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,7,26]]}}}